Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Seven drug companies are making “deprioritized” compounds available to British researchers through a new agreement with the U.K.’s Medical Research Council. AstraZeneca, GlaxoSmithKline, Janssen, Eli Lilly & Co., Pfizer, Takeda, and UCB will each provide MRC with a number of molecules they are no longer developing. Academic scientists then can apply for MRC funding to use them in research projects. The program builds on an earlier compound-sharing agreement between MRC and AstraZeneca.
This article has been sent to the following recipient: